- http://www.hivandhepatitis.com/recent/2011/0506_2011_c.html
2011
The HIV protease inhibitor lopinavir (the main drug in Kaletra) blocked viral proteasome activitation and selectively killed pre-cancerous cervical cells infected with human papillomavirus (HPV).

Aber: sie müssen wohl erst eine Creme davon erfinden, weil Tabletten sind zu schwach

- https://www.telegraph.co.uk/women/womens...cal-cancer.html
2014
Almost by chance, the Hampsons discovered in their lab at St Mary’s Hospital, Manchester, that the drug lopinavir, licensed for the treatment of HIV, attacks the strain of human papillomavirus (HPV) that causes virtually all cases of cervical cancer. An as-yet unpublished clinical trial has found that lopinavir capsules, when inserted into the vagina, appear to kill off abnormal cells in the cervix. There appear to be no side effects.

“We literally smashed up tablets and stuck them into cultures both of HPV and cervical cancer cells,” recalls Dr Hampson. Several seemed to have activity against HPV and cancer, but lopinavir was the most potent. “Lopinavir was remarkably toxic. We could see the cells dying in the lab.”

By 2011, he says, they had shown that lopinavir was “multifunctional”, meaning it inhibited both viral proteins and the proteins in cancer cells. Still nothing had been proven clinically, and as Dr Hampson soon discovered, setting up a patient trial proved difficult.

Lopinavir is made by the US company Abbott Laboratories as part of a combination drug for HIV called Kaletra. The good news was that, as one of the most widely prescribed drugs worldwide and already licensed for both children and adults with HIV, it would not need extensive safety testing. The bad news was that it was only licensed for oral delivery. This formulation would not, at the strength needed, get enough of the drug delivered to the cervix.

“Our work showed we needed a 10-fold higher concentration of the drug at the site of infection – the cervix – than you can get by taking the drug orally,” says Dr Hampson. “The obvious solution was to reformulate the drug, so it could be applied locally as a cream or pessary, and organise a clinical trial.”

But the cost of reformulating the drug meant there was little interest from drug companies, cancer charities or research agencies. Then one of Dr Hampson’s PhD students pointed out that one oral form of the drug available was a soft gelatin capsule, which might “melt very nicely” in the vagina, and could be trialled as a pessary.

“We had a 90 per cent treatment response in the high-grade group – we couldn’t believe it,” he says. Although high-grade disease can sometimes disappear spontaneously after a year or two, this is rare after three months.

-> extrem spannend zu lesen der Artikel. Also soft-tabletten Lopinavir haben sie praktisch einfach benützt als 'salbe'. Kommt man halt nicht ran, bzw weiß garnicht wie viel das kostet, wahrscheinlich viel. HIV medikament.
Sollen dann für Frauen mit Gebärmutterveränderung sein die hpv positiv sind.



https://www.standardmedia.co.ke/article/...cervical-cancer
2014
"820 women at KNH and finally settled on 40 patients who had cervical cancer.
“We put them on the HIV drug lopinavir for two weeks which they had to apply in the birth canal on their own at home. This was for a period of two weeks while we kept monitoring them. The results were amazing with a cure rate of almost 90 per cent confirmed after three months,” said Dr Maranga, a gynecologist.
High doses
Ordinarily, the drug is used orally by HIV patients but to treat cancer, Dr Maranga explained it would require very high doses which could be toxic hence they designed a method of applying it directly into the birth canal.
He said earlier laboratory studies had shown the drug to kill the human papilloma virus (HPV), which causes most cervical cancers but this was the first time anywhere in the world human trials had been carried out.

His co-investigator Prof Peter Gichangi of the University of Nairobi said they will now move on to Phase II and then III trials, which could require up to 5,000 women.
“If all goes well in these proposed trials, we should have a product in the market in about seven years time.”"

-> Also in etwa 2022 sollte das rauskommen